These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 21701502)

  • 1. Novel therapeutic targets for the treatment of heart failure.
    Tamargo J; López-Sendón J
    Nat Rev Drug Discov; 2011 Jun; 10(7):536-55. PubMed ID: 21701502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sex differences in heart failure medications targeting the renin-angiotensin-aldosterone system.
    Nicolaou PA
    Eur J Pharmacol; 2021 Apr; 897():173961. PubMed ID: 33617824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G; Bhat G
    Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure.
    Valluri A; Struthers AD; Lang CC
    Curr Heart Fail Rep; 2014 Mar; 11(1):31-9. PubMed ID: 24234398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
    Sexton DJ
    Circ Heart Fail; 2014 May; 7(3):536. PubMed ID: 24847129
    [No Abstract]   [Full Text] [Related]  

  • 7. Novelties in Therapy of Chronic Heart Failure.
    Doimo S; Pavan D
    Heart Fail Clin; 2021 Apr; 17(2):255-262. PubMed ID: 33673949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure.
    Oliveros E; Oni ET; Shahzad A; Kluger AY; Lo KB; Rangaswami J; McCullough PA
    Cardiorenal Med; 2020; 10(2):69-84. PubMed ID: 32062648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin-angiotensin-aldosterone system inhibition in heart failure with mid-ranged ejection fraction: A systematic review and meta-analysis.
    Memon MM; Yamani N; Asmi N; Agrawal R; Khan MS
    Eur J Prev Cardiol; 2020 Dec; 27(19):2371-2373. PubMed ID: 30966823
    [No Abstract]   [Full Text] [Related]  

  • 10. [Role of RAAS inhibitors for the treatment of heart failure].
    Murohara T
    Nihon Rinsho; 2012 Sep; 70(9):1577-81. PubMed ID: 23012806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: Statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology.
    Mewton N; Girerd N; Boffa JJ; Courivaud C; Isnard R; Juillard L; Lamblin N; Legrand M; Logeart D; Mariat C; Meune E; Sabouret P; Sebbag L; Rossignol P
    Arch Cardiovasc Dis; 2020 Oct; 113(10):660-670. PubMed ID: 32660835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Miller AB; Srivastava P
    Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological therapy of heart failure with reduced ejection fraction].
    Wieser M; Rhyner D; Martinelli M; Suter T; Schnegg B; Bösch C; Wigger O; Dobner S; Hunziker L
    Ther Umsch; 2018 Sep; 75(3):180-186. PubMed ID: 30145973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypertension in patients with heart failure].
    Takekoshi N; Asaji T; Tada N
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():478-83. PubMed ID: 15171419
    [No Abstract]   [Full Text] [Related]  

  • 15. Heart failure therapy: what should clinicians believe?
    Fang JC
    JAMA; 2012 Nov; 308(20):2144-6. PubMed ID: 23188032
    [No Abstract]   [Full Text] [Related]  

  • 16. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
    JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What constitutes optimal neurohumoral antagonism in chronic heart failure?
    Tajik AA; Dickstein K
    Heart; 2016 Dec; 102(23):1922-1932. PubMed ID: 27742799
    [No Abstract]   [Full Text] [Related]  

  • 18. Real or Perceived: Hyperkalemia Is a Major Deterrent for Renin-Angiotensin Aldosterone System Inhibition in Heart Failure.
    McCullough PA; Rangaswami J
    Nephron; 2018; 138(3):173-175. PubMed ID: 29207385
    [No Abstract]   [Full Text] [Related]  

  • 19. Aldosterone in heart failure: pathophysiology and treatment.
    Struthers AD
    Curr Heart Fail Rep; 2004 Dec; 1(4):171-5. PubMed ID: 16036041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aldosterone blockade in heart failure. So much for so little].
    González-Juanatey JR; Mazón Ramos P
    Med Clin (Barc); 2002 Jun; 118(20):779-81. PubMed ID: 12049694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.